CL2016001008A1 - Formulaciones de inyección con base en aceite de sésamo. - Google Patents
Formulaciones de inyección con base en aceite de sésamo.Info
- Publication number
- CL2016001008A1 CL2016001008A1 CL2016001008A CL2016001008A CL2016001008A1 CL 2016001008 A1 CL2016001008 A1 CL 2016001008A1 CL 2016001008 A CL2016001008 A CL 2016001008A CL 2016001008 A CL2016001008 A CL 2016001008A CL 2016001008 A1 CL2016001008 A1 CL 2016001008A1
- Authority
- CL
- Chile
- Prior art keywords
- sesame oil
- formulations based
- injection formulations
- formulation
- injection
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002347 injection Methods 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title abstract 2
- 239000008159 sesame oil Substances 0.000 title 1
- 235000011803 sesame oil Nutrition 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 230000002914 neoplasic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>UNA FORMULACION FARMACEUTICA ADECUADA PARA INYECCION QUE COMPRENDE ACEITE DE SESAMO, ETANOL Y UN COMPUESTO DERIVADO DE IMIDAZOPIRIDINA, MODIFICADOR DE LA RESPUESTA INMUNITARIA; METODO PARA ELABORAR LA FORMULACION; METODO PARA SUMINISTRAR LA FORMULACION, UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD NEOPLASICA.</p> <p><br /> <br /> </p> <p> </p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361900255P | 2013-11-05 | 2013-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001008A1 true CL2016001008A1 (es) | 2017-01-13 |
Family
ID=53041971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001008A CL2016001008A1 (es) | 2013-11-05 | 2016-04-28 | Formulaciones de inyección con base en aceite de sésamo. |
Country Status (22)
Country | Link |
---|---|
US (2) | US11020486B2 (es) |
EP (1) | EP3065741B1 (es) |
JP (2) | JP6446054B2 (es) |
KR (1) | KR102258645B1 (es) |
CN (1) | CN105873587B (es) |
AU (2) | AU2014347059B2 (es) |
CA (1) | CA2926736C (es) |
CL (1) | CL2016001008A1 (es) |
CR (1) | CR20160214A (es) |
DO (1) | DOP2016000080A (es) |
GT (1) | GT201600082A (es) |
IL (1) | IL244840B (es) |
MX (1) | MX2016005996A (es) |
NI (1) | NI201600061A (es) |
PE (1) | PE20160849A1 (es) |
PH (1) | PH12016500820A1 (es) |
RU (1) | RU2687279C2 (es) |
SG (2) | SG11201603218UA (es) |
SV (1) | SV2016005191A (es) |
TW (1) | TW201609150A (es) |
WO (1) | WO2015069535A1 (es) |
ZA (1) | ZA201603792B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201840316A (zh) * | 2017-01-12 | 2018-11-16 | 美商麥迪紐有限責任公司 | Toll樣受體7/8激動劑之安全性和藥物活性 |
KR102051808B1 (ko) | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US610929A (en) | 1898-09-20 | trapp | ||
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
GB2167408B (en) | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
EP0267617B1 (en) * | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
JPH0262483A (ja) | 1988-08-24 | 1990-03-02 | Nec Kyushu Ltd | ボールバルブ |
US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
JP2005519990A (ja) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
NZ532769A (en) * | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
WO2005001022A2 (en) * | 2003-04-10 | 2005-01-06 | 3M Innovative Properties Company | Methods and compositions for enhancing immune response |
US8239070B1 (en) | 2003-06-27 | 2012-08-07 | Intellicon, Inc. | Root cause and system enhancement analysis |
CA2535338C (en) | 2003-08-14 | 2013-05-28 | 3M Innovative Properties Company | Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
EP1830880A4 (en) * | 2004-12-30 | 2008-03-26 | Coley Pharm Group Inc | MULTI-CHANNEL ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS |
EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
WO2010096795A1 (en) | 2009-02-23 | 2010-08-26 | Clemson University | Fabrication of nanofiber reinforced structures for tissue engineering |
US20130023578A1 (en) | 2009-12-31 | 2013-01-24 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of c-Met expression and anticancer composition containing the same |
CA2792517C (en) * | 2010-03-09 | 2020-03-24 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations |
US9242980B2 (en) * | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体 |
US9678976B2 (en) | 2014-07-21 | 2017-06-13 | Red Hat, Inc. | Distributed deduplication using locality sensitive hashing |
AU2015296214B2 (en) * | 2014-08-01 | 2019-11-07 | Board Of Regents, The University Of Texas System | Methods and therapeutic combinations for treating tumors |
-
2014
- 2014-10-30 AU AU2014347059A patent/AU2014347059B2/en active Active
- 2014-10-30 SG SG11201603218UA patent/SG11201603218UA/en unknown
- 2014-10-30 RU RU2016119488A patent/RU2687279C2/ru active
- 2014-10-30 EP EP14860736.9A patent/EP3065741B1/en active Active
- 2014-10-30 US US15/032,773 patent/US11020486B2/en active Active
- 2014-10-30 KR KR1020167014995A patent/KR102258645B1/ko active IP Right Grant
- 2014-10-30 CR CR20160214A patent/CR20160214A/es unknown
- 2014-10-30 CA CA2926736A patent/CA2926736C/en active Active
- 2014-10-30 WO PCT/US2014/063095 patent/WO2015069535A1/en active Application Filing
- 2014-10-30 CN CN201480058605.4A patent/CN105873587B/zh active Active
- 2014-10-30 SG SG10201803802YA patent/SG10201803802YA/en unknown
- 2014-10-30 JP JP2016552233A patent/JP6446054B2/ja active Active
- 2014-10-30 MX MX2016005996A patent/MX2016005996A/es active IP Right Grant
- 2014-10-30 PE PE2016000539A patent/PE20160849A1/es unknown
- 2014-11-04 TW TW103138238A patent/TW201609150A/zh unknown
-
2016
- 2016-03-30 IL IL244840A patent/IL244840B/en active IP Right Grant
- 2016-04-11 DO DO2016000080A patent/DOP2016000080A/es unknown
- 2016-04-28 CL CL2016001008A patent/CL2016001008A1/es unknown
- 2016-05-03 SV SV2016005191A patent/SV2016005191A/es unknown
- 2016-05-03 GT GT201600082A patent/GT201600082A/es unknown
- 2016-05-03 PH PH12016500820A patent/PH12016500820A1/en unknown
- 2016-05-04 NI NI201600061A patent/NI201600061A/es unknown
- 2016-06-03 ZA ZA2016/03792A patent/ZA201603792B/en unknown
-
2017
- 2017-12-06 AU AU2017272198A patent/AU2017272198B2/en active Active
-
2018
- 2018-11-29 JP JP2018223435A patent/JP2019052166A/ja active Pending
-
2021
- 2021-04-28 US US17/242,578 patent/US20210244819A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002034A1 (es) | Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776) | |
CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
CL2016000925A1 (es) | Inhibidores de bromodominio | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
CL2015002837A1 (es) | Compuestos de piridinilpirazoloquinolina. | |
CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
CL2015003635A1 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. | |
CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
CR20160061A (es) | Formulación estable líquida de etelcalcetide (amg 461) | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
EA201791716A1 (ru) | Фармацевтический состав | |
PE20170702A1 (es) | Derivados estabilizados de adrenomedulina y uso de los mismos | |
CL2016001008A1 (es) | Formulaciones de inyección con base en aceite de sésamo. | |
UY35823A (es) | Profármacos de antagonista de nmda | |
NZ712341A (en) | A crystalline form of an anxiolytic compound | |
MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
CL2018000489A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
AR095638A1 (es) | Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario | |
CL2016002256A1 (es) | Un proceso mejorado para la preparación de exametazima |